Folic acid

Colorectal cancer one of the mostly found cancer in all over the world. Mortality rate by this cancer is high compared to other types o cancers. Early diagnosis of this cancer is required to treat this cancer. Many drugs are being used to treat this disease but they all have many side effects so in study we tried to overcome this issue by treating this cancer with supplements. We used male albino SD rats to conduct this study. We divided the rats into 7 groups in which 4 of them were given Azoxymethane (AOM) to induce the colo-rectal cancer while remaining 3 were kept control. One group with AOM was not given any treatment while 3 received folic acid dose (20, 40, and 60) respectively along with Vitamin A, C, and E supplementation. Control groups without AMO were also treated with same doses of folic acid in order to compare the results. Results reveal that Folic acid improved GSH, TAC, Lipid peroxidation and superoxide dismutase levels in the AMO treated groups. These tests were also improved in control groups with folic acid and vitamin supplementation. We conclude that Folic acid is found very affective against the colorectal cancer without harming the natural mechanisms in the body. The aim of this study, to evaluate the preventive and protective measure of different doses of folic acid with normal therapeutic doses of vitamin A, C and E against azoxymethane induce colon cancer in rat.

Pegylated-interferon α-2a and ribavirin (PIFN/RBV), the current standard treatment for hepatitis C virus (HCV) infection in Egypt, is frequently associated with hematological adverse effects, leading to high treatment discontinuation rates. The objective of the present study is to explore the effectiveness of intervening with folic acid (F) and/or vitamin B complex (B) compared with placebo (C) in HCV-treatment Egyptian patients for the management of treatment-induced deterioration of health related quality of life (HRQOL) as well as hematological parameter. In a randomized controlled trial, one hundred and sixty subjects were randomly assigned to receive PIFN/RBV in addition to BF, B, F, or C. Blood samples were collected at different time points during 48 weeks and at 12 and 24 weeks post treatment for complete blood count and for HCV RNA real time PCR. Short form SF 36V2 questionnaire were used to assess HRQOL at various time during and post treatment. Egyptian HCV patients treated with PIFN/RBV showed deterioration of HRQOL which were correlated with deterioration in the measured hematological parameter. Supplementation with vitamin B complex plus folic acid significantly (P<0.001) decreased the deterioration observed in physical and mental health as well as complete blood count. Supplementation with either vitamin B complex or folic acid were also effective but with lower potency than their combination. BF supplementation can reduce adverse effects of PIFN/RBV therapy in chronic hepatitis C patients, which may improve patients’ HRQOL and their adherence to combination antiviral therapy.